Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury.

被引：30

作者：

Dumitrascu R. ^{[1
]}

Koebrich S. ^{[1
]}

Dony E. ^{[1
]}

Weissmann N. ^{[1
]}

Savai R. ^{[1
]}

Pullamsetti S.S. ^{[1
]}

Ghofrani H.A. ^{[1
]}

Samidurai A. ^{[1
]}

Traupe H. ^{[1
]}

Seeger W. ^{[1
]}

Grimminger F. ^{[1
]}

Schermuly R.T. ^{[1
]}

机构：

[1] University of Giessen Lung Center, Giessen

来源：

BMC Pulmonary Medicine | / 8卷 / 1期

关键词：

Pulmonary Hypertension; Acute Lung Injury; Lung Compliance; Lung Edema; Diffuse Alveolar Damage;

D O I：

10.1186/1471-2466-8-25

中图分类号：

学科分类号：

摘要：

BACKGROUND: New animal models of chronic pulmonary hypertension in mice are needed. The injection of monocrotaline is an established model of pulmonary hypertension in rats. The aim of this study was to establish a murine model of pulmonary hypertension by injection of the active metabolite, monocrotaline pyrrole. METHODS: Survival studies, computed tomographic scanning, histology, bronchoalveolar lavage were performed, and arterial blood gases and hemodynamics were measured in animals which received an intravenous injection of different doses of monocrotaline pyrrole. RESULTS: Monocrotaline pyrrole induced pulmonary hypertension in Sprague Dawley rats. When injected into mice, monocrotaline pyrrole induced dose-dependant mortality in C57Bl6/N and BALB/c mice (dose range 6-15 mg/kg bodyweight). At a dose of 10 mg/kg bodyweight, mice developed a typical early-phase acute lung injury, characterized by lung edema, neutrophil influx, hypoxemia and reduced lung compliance. In the late phase, monocrotaline pyrrole injection resulted in limited lung fibrosis and no obvious pulmonary hypertension. CONCLUSION: Monocrotaline and monocrotaline pyrrole pneumotoxicity substantially differs between the animal species.

引用

共 282 条

[1]

Humbert M(2004)Cellular and molecular pathobiology of pulmonary arterial hypertension J Am Coll Cardiol 43 13S-24S

[2]

Morrell NW(2004)Treatment of pulmonary arterial hypertension N Engl J Med 351 1425-1436

[3]

Archer SL(2001)Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension Pharmacol Ther 92 1-20

[4]

Stenmark KR(1997)Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension Am J Pathol 151 1019-1025

[5]

MacLean MR(1993)Fetal ductus arteriosus ligation. Pulmonary vascular smooth muscle biochemical and mechanical changes Circ Res 72 588-596

[6]

Lang IM(1997)Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus J Clin Invest 99 1179-1186

[7]

Christman BW(2000)Systemic lobar shunting induces advanced pulmonary vasculopathy J Thorac Cardiovasc Surg 120 88-98

[8]

Weir EK(1998)eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow Am J Physiol 274 L1058-L1065

[9]

Eickelberg O(2006)Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange Proc Natl Acad Sci USA 103 19093-19098

[10]

Voelkel NF(1996)Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats J Clin Invest 97 2491-2498

← 1 2 3 4 5 6 7 8 9 10 →